Immunome (NASDAQ:IMNM) Director Sells $2,003,396.34 in Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 83,094 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $24.11, for a total value of $2,003,396.34. Following the completion of the transaction, the director directly owned 125,410 shares in the company, valued at approximately $3,023,635.10. The trade was a 39.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The shares were sold at an average price of $24.20, for a total transaction of $409,125.20.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The shares were sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Price Performance

Shares of IMNM opened at $24.16 on Friday. The stock has a market capitalization of $2.74 billion, a PE ratio of -10.15 and a beta of 2.07. Immunome, Inc. has a 12-month low of $7.96 and a 12-month high of $27.65. The business’s fifty day moving average price is $21.01 and its 200 day moving average price is $21.87.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.12. As a group, research analysts anticipate that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on IMNM shares. Truist Financial lifted their price target on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, May 28th. HC Wainwright reissued a “buy” rating on shares of Immunome in a report on Thursday. Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Citigroup reaffirmed a “buy” rating on shares of Immunome in a research note on Thursday. Finally, Leerink Partners decreased their target price on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. Thirteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Immunome presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.17.

Hedge Funds Weigh In On Immunome

Hedge funds have recently bought and sold shares of the business. KBC Group NV bought a new stake in Immunome during the first quarter valued at about $60,000. BNP Paribas Financial Markets lifted its holdings in shares of Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after buying an additional 2,909 shares during the last quarter. Strs Ohio bought a new stake in shares of Immunome in the fourth quarter valued at approximately $64,000. Tower Research Capital LLC TRC increased its position in Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after acquiring an additional 3,802 shares during the period. Finally, Russell Investments Group Ltd. bought a new position in Immunome during the third quarter worth $76,000. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.